Загрузка...

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

BACKGROUND: Selumetinib (AZD6244, ARRY-142886) is a second generation MEK inhibitor that is currently in clinical trials for various solid malignancies. MEK kinase inhibitors are associated with dermatologic toxicities. While reactions affecting the skin, hair and nails to other targeted agents, suc...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Invest New Drugs
Главные авторы: Balagula, Yevgeniy, Barth, Katherine, Busam, Klaus J., Lacouture, Mario E., Chapman, Paul B., Myskowski, Patricia L.
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691597/
https://ncbi.nlm.nih.gov/pubmed/20978926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9567-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!